Scancell Holdings part of the new cancer revolution The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology. [View article] Tuesday 25 September 2018 13:20 Categories: Immunobody Media Coverage Modi-1 Moditope SCIB1 SCIB2 Year - 2018 Previous Post << >> Next Post